 Ana Vujovic
Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 4 | 2025 | 688 | 0.810 |
Why?
| | Hematopoietic Stem Cells | 4 | 2026 | 435 | 0.500 |
Why?
| | Neoplastic Stem Cells | 3 | 2025 | 409 | 0.420 |
Why?
| | Oxidative Stress | 7 | 2014 | 1361 | 0.380 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2025 | 60 | 0.360 |
Why?
| | Clinical Laboratory Techniques | 1 | 2010 | 96 | 0.290 |
Why?
| | Hypercholesterolemia | 1 | 2010 | 95 | 0.290 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 368 | 0.270 |
Why?
| | Cholesterol, LDL | 1 | 2010 | 360 | 0.270 |
Why?
| | Aryldialkylphosphatase | 6 | 2014 | 17 | 0.250 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2025 | 74 | 0.230 |
Why?
| | Niacinamide | 1 | 2026 | 104 | 0.230 |
Why?
| | Myelodysplastic Syndromes | 1 | 2026 | 165 | 0.210 |
Why?
| | Hematopoiesis | 2 | 2022 | 193 | 0.200 |
Why?
| | ELAV-Like Protein 1 | 1 | 2023 | 17 | 0.190 |
Why?
| | Leukemia | 1 | 2025 | 246 | 0.190 |
Why?
| | Molecular Targeted Therapy | 1 | 2025 | 441 | 0.180 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 66 | 0.180 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2021 | 27 | 0.170 |
Why?
| | Lipids | 4 | 2012 | 707 | 0.150 |
Why?
| | RNA-Binding Proteins | 1 | 2023 | 447 | 0.150 |
Why?
| | Antioxidants | 2 | 2014 | 550 | 0.140 |
Why?
| | Atherosclerosis | 2 | 2012 | 409 | 0.140 |
Why?
| | Cell Differentiation | 2 | 2023 | 2050 | 0.130 |
Why?
| | Transcription Factors | 1 | 2025 | 1736 | 0.130 |
Why?
| | Antineoplastic Agents | 1 | 2025 | 2219 | 0.100 |
Why?
| | Serbia | 2 | 2011 | 7 | 0.100 |
Why?
| | Hyperlipidemias | 1 | 2012 | 120 | 0.090 |
Why?
| | Reference Values | 2 | 2011 | 798 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3551 | 0.090 |
Why?
| | Volleyball | 1 | 2011 | 9 | 0.080 |
Why?
| | Physical Education and Training | 1 | 2011 | 70 | 0.080 |
Why?
| | Malnutrition | 1 | 2012 | 86 | 0.080 |
Why?
| | Signal Transduction | 2 | 2025 | 5226 | 0.080 |
Why?
| | Smoking | 2 | 2014 | 1477 | 0.080 |
Why?
| | Humans | 16 | 2026 | 145785 | 0.070 |
Why?
| | Lipoproteins | 1 | 2010 | 166 | 0.070 |
Why?
| | Weight Gain | 1 | 2012 | 561 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 611 | 0.070 |
Why?
| | Lipoproteins, LDL | 1 | 2008 | 119 | 0.070 |
Why?
| | Lipoproteins, HDL | 1 | 2008 | 100 | 0.070 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2026 | 26 | 0.060 |
Why?
| | Pregnancy | 3 | 2014 | 7216 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2012 | 599 | 0.060 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2012 | 668 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 382 | 0.060 |
Why?
| | Asparagine | 1 | 2025 | 35 | 0.060 |
Why?
| | Cardiolipins | 1 | 2025 | 82 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 169 | 0.050 |
Why?
| | Protein Biosynthesis | 1 | 2025 | 452 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 936 | 0.040 |
Why?
| | Mice | 3 | 2025 | 18358 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3418 | 0.040 |
Why?
| | Coronary Artery Disease | 1 | 2008 | 750 | 0.040 |
Why?
| | Malondialdehyde | 2 | 2012 | 31 | 0.040 |
Why?
| | Inflammation | 2 | 2012 | 2885 | 0.040 |
Why?
| | Spindle Apparatus | 1 | 2021 | 95 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 322 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2012 | 3634 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 883 | 0.040 |
Why?
| | Regression Analysis | 2 | 2012 | 1001 | 0.040 |
Why?
| | Adult | 6 | 2014 | 40882 | 0.040 |
Why?
| | Linear Models | 2 | 2012 | 849 | 0.040 |
Why?
| | Proteins | 1 | 2025 | 1023 | 0.040 |
Why?
| | Mitochondria | 1 | 2025 | 994 | 0.040 |
Why?
| | Cytokines | 1 | 2026 | 2069 | 0.030 |
Why?
| | Dietary Supplements | 2 | 2014 | 584 | 0.030 |
Why?
| | Renal Dialysis | 2 | 2012 | 466 | 0.030 |
Why?
| | Female | 8 | 2014 | 79045 | 0.030 |
Why?
| | Animals | 3 | 2025 | 38106 | 0.030 |
Why?
| | Phenotype | 3 | 2011 | 3170 | 0.030 |
Why?
| | Proteomics | 1 | 2022 | 1188 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2019 | 1247 | 0.030 |
Why?
| | Thiobarbituric Acid Reactive Substances | 1 | 2014 | 29 | 0.030 |
Why?
| | Middle Aged | 3 | 2012 | 36309 | 0.020 |
Why?
| | Advanced Oxidation Protein Products | 1 | 2012 | 1 | 0.020 |
Why?
| | Vitamins | 1 | 2014 | 184 | 0.020 |
Why?
| | Apoptosis | 1 | 2021 | 2445 | 0.020 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2012 | 75 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2019 | 2514 | 0.020 |
Why?
| | Male | 4 | 2012 | 73012 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2012 | 308 | 0.020 |
Why?
| | Cholesterol | 1 | 2012 | 408 | 0.020 |
Why?
| | Young Adult | 3 | 2012 | 14254 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 528 | 0.020 |
Why?
| | Triglycerides | 1 | 2012 | 520 | 0.020 |
Why?
| | Dyslipidemias | 1 | 2012 | 184 | 0.020 |
Why?
| | Risk Assessment | 2 | 2011 | 3752 | 0.020 |
Why?
| | Biomarkers | 2 | 2011 | 4302 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1300 | 0.020 |
Why?
| | Athletic Performance | 1 | 2011 | 78 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 971 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2011 | 289 | 0.020 |
Why?
| | Paraoxon | 1 | 2008 | 2 | 0.020 |
Why?
| | Gestational Age | 1 | 2011 | 990 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2011 | 1069 | 0.020 |
Why?
| | Area Under Curve | 1 | 2008 | 332 | 0.020 |
Why?
| | Organophosphorus Compounds | 1 | 2008 | 84 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1547 | 0.020 |
Why?
| | Athletes | 1 | 2011 | 425 | 0.020 |
Why?
| | Particle Size | 1 | 2008 | 381 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 2012 | 712 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2968 | 0.010 |
Why?
| | Body Mass Index | 1 | 2012 | 2447 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2139 | 0.010 |
Why?
| | Blood Glucose | 1 | 2011 | 2344 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 7134 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 8078 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2191 | 0.010 |
Why?
| | Risk Factors | 1 | 2011 | 10919 | 0.010 |
Why?
| | Adolescent | 1 | 2012 | 22577 | 0.010 |
Why?
| | Child | 1 | 2012 | 22740 | 0.010 |
Why?
|
|
Vujovic's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|